SecBot SecBot
SECBOTREPLAY Home › Report › KPTI

KPTI · Karyopharm Therapeutics has entered into a forbearance agreement with…

Karyopharm Therapeutics Inc. · 8-K filed Sep 11, 2026 at 07:45 ET

At the news

BEARISHIMPACT 9/10

8-K filed Sep 11, 2026 at 07:45 ET

Karyopharm Therapeutics has entered into a forbearance agreement with 100% of its term loan lenders, convertible noteholders, and royalty investors, after failing to make a ~$15.8M principal payment due September 10, 2026, and not expecting to pay cash interest due September 30, 2026. The forbearance period runs to October 15, 2026, providing a short window to negotiate a restructuring, raise equity, or pursue strategic alternatives, but the company explicitly states that absent additional funding, it will be unable to continue as a going concern and may seek bankruptcy protection. As consideration, the company will issue $20M of convertible preferred stock (convertible at $1.62/share) to the consenting lenders, adding further dilution risk to common equity holders.

  • Company did not pay ~$15.8M principal installment due September 10, 2026 under its Term Loan Credit Agreement.
  • Company does not expect to pay cash interest due September 30, 2026 under the Credit Agreement and Indentures.
  • Company did not make cash interest payments on the 2028 and 2029 Notes on June 30, 2026 (~$2.8M in unpaid interest).
  • Forbearance period runs only until October 15, 2026, providing a very short runway.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access